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Intravenous, Oral Pharmacokinetics, and Oral Dosing of FK 506 in 
Small Bowel Transplant Patients 
A. Jain. R. Venkataramanan. S. Todo. K. Abu-Elmagd. J. Fung. V. Warty. A. Tzakis. J. Reyes, 
M. Alessiani, and T.E. Starzi 
FK 506 is a new macrolide with potent immunosuppres-
sive activity. Use of this drug is associated with 
reduced incidence of rejection following liver. kidney. and 
heart transplantation. 1-4 Recently, FK 506 has been shown 
to be effective in small bowel transplantation. S It is known 
that FK 506 absorption is not influenced by the presence or 
absence of bile.6--8 The aims of this study are to: (\) 
determme pharmacokinetics of FK 506 after intravenous 
(IV) dose in small bowel transplant patients: and (2) to 
determine the absorption of FK 506 following oral admin-
istratIOn. 
MATERIALS AND METHODS 
Five patients (3 male and 2 female: ages 31. 2. '27. 4. and 3 yearsl 
underwent small bowel transplantation between May 1990 and 
March 1991. The first patient received only a small bowel trans-
plantation. while the other four patients had a liver and small 
bowel transplanted simultaneously. FK 506 was administered at a 
dose of 0.1 to 0.15 mg/kg per dav as a 4-hour IV infusion or as a 
continuous infusion in all the patients. Subsequent dose adjust-
ments were made depending on the clinical situation of the 
patient. the plasma FK 506 concentration. renal function. liver 
function. and rejection episodes. Oral fK 506 therapy was initi-
ated when patients could tolerate oral intake. Pharmacokinetic 
studies were carried out over a dosing interval of 12 or 24 hours. 
Multiple blood samples were obtained over the dosing intervals, 
and plasma was separated at 37"C and analyzed for FK 506 
concentrations by ELISA.9. 10 
Table 1. Pharmacoklnetlca of FK 506 In SlMllBowei Transplent 
P ........ 
CIa ___ 
(nUmi"I per Half.ufe Peak Time 
Patient # Study # kilograml (hourISl AbIorpIIon "- (Hoursl 
1 12.7 , 1.5 25 4 
2 13.2 6.9 10· 2 
3 29 3 
2 25.2 
2 21.4 31 5 
3 1 21 S" 0.5 
2 17 51 2 
3 21 17 2 
4 1 27 89 3 
2 28.3 93 4 
5 1 53 
2 25 
3 29 16 2 
'Proximal stoma was open at this time. 
Table 2. M ..... Oral FK 506 Dosage Requirements (mglkg per 
day, and U ..... FK 506 Trough Pie..,. Concentnltlon (mglmL) 
2 4 6 8 12 
Patient FK 506 Months Months Months Months Months 
Children Dosage 0.087 0.22 0.3 0.15 0.08" 
Level 0.3 0.9 0.4 0.9 0.4" 
Adults Dosage 0.32" 0.28 0.18 0.14 0.15 
Level 2.3' 2.2 2.0 1.4 0.6 
'n ~ 1 Patient. 
RESULTS 
As shown in Table I, the plasma clearance of the FK 506 
ranged from 12.7 to 53 mUmin per kilogram. The oral 
absorption of FK 506 was low (5% to 10%) when the 
proximal stoma was open in two patients. The oral bio-
availability ranged from 16% to 93% (mean 43%) when the 
stoma was closed. The time to peak plasma concentrations 
after oral dose was 30 minutes to 5 hours (mean 2.8 hours). 
The oral maintenance dose (mglkg per day) of FK 506 in 
adults (n = 2) and children (n = 3) at 2, 4, 6, 8, and 12 
months posttransplant and the corresponding trough con-
centration of FK 506 in plasma are shown in Table 2. The 
dose of FK 506 and the plasma concentrations achieved in 
small bowel transplant patients are comparable to those 
observed in pediatric and adult liver transplant patients. II 
CONCLUSIONS 
The pharmacokinetic parameters of FK 506 in small bowei 
transplant patients are similar to our observations in other 
organ transplant patients. FK 506 is well absorbed from 
transplanted small bowel. FK 506 dosing regimen similar 
to that used in liver transplant patients can be used 
effectively in small bowel transplant patients. 
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